Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

NCT00203866 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Stopped Study completed

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: G250 peptide
DRUG: IL-2

Sponsor

University of Chicago